Human immunodeficiency virus patients with low CD4 counts are more likely to have precancerous polyps identified during index colonoscopy

Table 1 Baseline characteristics for CD4 count < 500 and CD4 count > 500 groups

Clinical features	Parameter, n = 207 total	Controlled, n = 104	Uncontrolled, n = 103	P value
Age	Yr	55.9 (47-71)	56.3 (39-76)	0.6369
Sex	Male	46.15	70.87	0.0004
Race	Black	93.27	90.29	0.8201
	Hispanic	3.85	5.83
	White	2.88	2.91
Ethnicity	African American	26.32	39.29	0.6478
	Afro-Caribbean	31.58	25.00
	Hispanic	21.05	25.00
	Other	21.05	10.71
BMI in kg/m2		28.0	26.2	0.0276
Diabetes mellitus	Diabetic	14.42	11.76	0.6807
Smoking	Current	18.27	27.18	0.2451
Insurance	HIV specific	8.65	14.56	0.4638
	Medicare	10.58	14.56
	Medicaid	60.58	53.40
	Private	16.35	16.50
	Self-Pay	1.92	0.97

Data are presented as mean (range) or %, except BMI which is presented as mean. BMI: Body mass index; HIV: Human immunodeficiency virus.

Table 2 Fisher’s exact two-sided tests for the incidence of polyps in the CD4 count > 500 and CD4 count < 500 groups

Variable	Controlled, n = 104	Uncontrolled, n = 103	P value
Any polyp	5 (4.81)	18 (17.48)	0.0040
Polyp type			0.0736
Adenoma	1 (0.96)	6 (5.83)
Hyperplastic	3 (2.88)	4 (3.88)
Serrated	1 (0.96)	5 (4.85)
Precancerous	2 (1.92)	11 (10.68)	0.0102
Advanced adenoma	1 (0.96)	6 (5.83)	0.0651
Right colon adenoma	1 (0.96)	4 (3.88)	0.2119

Data are presented as n (%).

Table 3 Logistic regression of HIV control and precancerous polyps controlling for other variables

Variable	Odds ratio (95%CI)	P value
CD4 < 500 vs CD4 > 500	9.01 (1.69-47.97)	0.0100
Female vs male	2.58 (0.64-10.34)	0.1839
BMI	0.99 (0.89-1.11)	0.8956
NRTIs	1.50 (0.27-8.36)	0.6425
NNRTIs	10.23 (1.08-97.15)	0.0428
PIs	3.23 (0.35-29.98)	0.3032
FIs	0.44 (0.01-23.08)	0.6832
INSTIs	4.01 (0.23-69.67)	0.3403
CCR5 antagonists	15.39 (0.22-999.99)	0.2073

BMI: Body mass index; CI: Confidence interval; CCR5: C-C chemokine receptor 5; FIs: Fusion inhibitors; INSTI: Integrase strand transfer inhibitors; NNRTIs: Non-nucleoside reverse transcriptase inhibitors; NRTIs: Nucleoside reverse transcriptase inhibitors; PIs: Protease inhibitors.